Po‐Liang Lu

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)

Po‐Liang Lu, Yung-Ching Liu, Han Siong Toh et al. · International Journal of Antimicrobial Agents · 2012 · 200 citations

Life Sciences, Infectious Diseases, Microbiology +17

Proteus mirabilis urinary tract infection and bacteremia: Risk factors, clinical presentation, and outcomes

Chi‐Yu Chen, Yen‐Hsu Chen, Po‐Liang Lu et al. · Journal of Microbiology Immunology and Infection · 2012 · 169 citations

Life Sciences, Infectious Diseases, Microbiology +14

Risk Factors and Molecular Analysis of Community Methicillin-Resistant <i>Staphylococcus aureus</i> Carriage

Po‐Liang Lu, Lien-Chun Chin, Chien‐Fang Peng et al. · Journal of Clinical Microbiology · 2005 · 137 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

National Surveillance Study on Carbapenem Non-Susceptible Klebsiella pneumoniae in Taiwan: The Emergence and Rapid Dissemination of KPC-2 Carbapenemase

Sheng-Kang Chiu, Tsu‐Lan Wu, Yin-Ching Chuang et al. · PLoS ONE · 2013 · 130 citations · Full text

Veterinary Medicine, Infectious Diseases, Antimicrobial Resistance +16